AIkido Pharma Inc. (NASDAQ: AIKI) shares are -51.04% down in the year-to-date (YTD) period and have moved -6.32% or -$0.04 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +33.17% lower. Comparatively, the stock is -88.42% down YTD and -8.42% over the trailing 3-month period. If we look at the shorter duration, its week performance is -5.71% and -42.41% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
0 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $0.64. The forecasts give the AIkido Pharma Inc. stock a price target range of $1802.25 on the higher side while at least one analyst think the stock could plunge to a low of $1802.25. The two limits represent an upside potential of 99.96% or 99.96%.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 0 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 0 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Aeterna Zentaris Inc. (NASDAQ:AEZS), on the other hand, is trading around $0.47 with a market cap of $30.29M and analyst research firms have a positive stance on its shares. Some analysts are even forecasting $0 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Aeterna Zentaris Inc. (AEZS) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
AEZS’s operating expenses over the recent quarter were at $1.51 million. This represented a -2116.18% of the company’s total revenues which amounted $68000.0. With this in place, we can see that the company’s diluted EPS declined -$0.15 on the year-over-year period, growing to $0.01 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Dec 2019), the total assets figure advanced to $17.67 million from $19.64 million over the previous quarter. The company’s free cash flow for the quarter was -$4.85 million.
Insiders own 0.60% of the company shares, while shares held by institutions stand at 21.40% with a share float percentage of 21.85M. Investors are also buoyed by the number of investors in a company, with Aeterna Zentaris Inc. having a total of 32 institutions that hold shares in the company.